A groundbreaking development in fertility treatment has emerged from a university spin-out, with the potential to revolutionize IVF procedures. This innovative approach, backed by a substantial £3.5 million investment, aims to enhance success rates and accessibility for individuals seeking fertility assistance.
The key to this revolutionary method lies in a tiny liquid circuit, developed by IVFmicro, which has shown promising results in early trials. By improving embryo quality and quantity by an impressive 15%, this microfluidic device offers a fresh perspective on fertilization, moving away from the traditional petri dish method.
Embryos are carefully placed into microscopic channels, resembling the natural environment of the human body, which are as thin as a single hair. This innovative approach has the potential to significantly increase pregnancy chances and reduce the number of treatment cycles required.
IVFmicro's journey began as a research project at Leeds University in 2017, spearheaded by Helen Picton, a renowned professor of reproduction and early development, and Virginia Pensabene, a biomedical engineer specializing in microfluidics. Their combined expertise has led to a potential scientific breakthrough in reproductive medicine.
Helen Picton's notable achievements include her involvement in the first successful birth from a frozen ovary, as well as her work on fertility preservation for young cancer patients. Virginia Pensabene, on the other hand, has utilized microfluidics to model human organs for drug testing, bringing a unique perspective to the field.
"We've demonstrated that our method supports embryo development far better than standard methods," explains Virginia Pensabene. "By starting with a larger pool of high-quality embryos, we increase the chances of successful implantation and pregnancy."
The scientists have conducted experiments using large animal embryos, similar to human embryos, and found remarkable results. In their studies with sheep, the development rate doubled when using the microfluidic device, and the pregnancy rate increased significantly. This means that if the initial implantation attempt is unsuccessful, there are more high-quality embryos available for subsequent attempts.
The lead investor in this groundbreaking project is Northern Gritstone, an investment company that supports university spinouts and startups from the north of England. They are joined by the government's Innovate UK Investor Partnerships programme, further emphasizing the potential impact of this innovation.
Duncan Johnson, the CEO of Northern Gritstone, praises the initiative, stating, "IVFmicro exemplifies the exceptional innovation emerging from northern universities. By combining scientific excellence with a clear commercial vision, they address the societal challenge of infertility head-on."
This development raises intriguing questions about the future of fertility treatment. Could this microfluidic approach become the new standard in IVF procedures? What impact might it have on success rates and accessibility for individuals seeking assistance with fertility? We invite you to share your thoughts and engage in the discussion below.
